Navigation Links
Slavica Bio Chem MindUp Cancer Project (HTDS) Research Led To The Identification Of Genes Associated With Lung Cancer Promotion And Progression
Date:10/14/2009

    Using small molecules (purine analogs) scientists managed to reverse
    multidrug resistance in lung cancer, a common obstacle to successful
    cancer chemotherapy.

BELGRADE, Serbia, Oct. 14 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com (HTDS) - The issuer's Serbia based operating subsidiary Slavica BioChem www.slavicabiochem.com brings attention to its Mindup Bioresearch cancer project working on molecular origins of lung cancer: prospects for personalized prevention and therapy. On October 8 2009, the company posted a filing on Pink Sheets titled MindUp Cancer Project.

See direct link http://www.pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=24984

The company is using this opportunity to shed some light the significance of that filing. The MindUp group focused their investigation on inactivation of tumour suppressors as molecular marker events highly related to the pathogenesis of non-small cell lung carcinoma (NSCLC). To that end, they use paired tumour and normal lung tissue samples and blood obtained from patients with NSCLC after surgery. These results are presented at AACR (American Association for Cancer Research) Conference, Frontiers in Basic Cancer Research, http://www.aacr.org/home/scientists/meetings--workshops/frontiers-in-cancer-prevention-research.aspx October 8 - 11, 2009. Boston, Massachusetts, on poster entitled "The impact of inactivation of p53 and PTEN tumor suppressors on promotion and progression of human non-small cell lung carcinoma" (authors: Tijana Andjelkovic, Jasna Bankovic, Vedrana Milinkovic, Ana Podolski, Sabera Ru dijic, Nikola Tanic).

For example a recent article (see Globe and Mail Newspaper unauthorized link: http://www.theglobeandmail.com/news/national/canadians-uncover-the-cancer-map/article1316312/ ) reports that a team of British Columbia based scientists decodes the metastatic breast-cancer genome, shedding light on how tumours develop by understanding their mutations. The landmark achievement opens up a world of new ways to fight the disease - including personalized treatments.

MindUp cancer project scientists are of the opinion that their work is further advanced then the aforementioned, because their research led to the identification of genes associated with lung cancer promotion and progression, that may be potential biomarkers and useful for personalized therapy. Using small molecules (purine analogs) they managed to reverse multidrug resistance in lung cancer, a common obstacle to successful cancer chemotherapy.

As per the news release of yesterday Oct 13 2009 and a Filing of October 1 2009 Titled "Shareholders FAQ on Mellow Hope Slavica and HTDS" http://www.pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=24872 the company will be meeting early next week with the principal representatives of the Canadian Pharmaceutical company in Belgrade Serbia in regards to the Slavica Bio Chem's MindUp cancer project and its planned split off. The company sees this as a significant event for its MindUp cancer project, and brings attention to that filing.

Progress on the MindUp will be reported back at earliest by next week.

To receive regular updates on HTDS please sign up or opt in with your email address at this link http://www.minamargroup.com/updates/

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project", and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk; Investor Relations Department, (302) 357-9915 (IR), 1st Level Support Retail Clients General Inquiry, 1-800-365-4331 (M&A), Corporate Matters, www.minamargroup.com (M&A), www.minamargroup.net (IR)

SOURCE Hard to Treat Diseases


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Slavica Bio Chem (HTDS) Subsidiary Medical Team Message
2. Hard To Treat Diseases (HTDS) Slavica BioChem Update on Research Activities
3. Stem Cells Being Tested to Fight Pancreatic Cancer
4. New York Senators Chuck Schumer (D-NY) and Kirsten Gillibrand (D-NY) Join As Co-Sponsors of The Lung Cancer Mortality Reduction Act
5. SRI International Awarded a Department of Defense Laboratory-Clinical Transition Grant to Advance SRIs Novel Anticancer Agents for Prostate Cancer Treatment
6. Genes behind increasingly common form of cancer identified
7. Bioluminescence imaging used for eye cancer detection
8. Mastectomy Not First Choice for Most Breast Cancer Patients
9. Cash for Gold USA Continues to Fight Against Breast Cancer During National Breast Cancer Month
10. New old drug fights colon cancer
11. Dogs Helping to Advance Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 28, 2017 , ... Children and adolescents who enter the ... children in the general population. That’s because foster care is designed to protect ... While no fault of their own, youth who have experienced trauma often have ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... could substantially improve drug safety and minimize the cost of development. In this ... channel inhibition using cell lines and for cardiac toxicity using induced pluripotent stem ...
(Date:4/28/2017)... Abilene, Texas (PRWEB) , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... says, reveals which name the Creator responds to and which He does not. Yisrayl ... to believe which one is the true name, but he says with a little Scripture, ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates to ... ERP expert that specializes in long-term care, Brooke Grove now has the capability ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a ... he has leant his presence to an educational purpose as the host of the ... one being cancer. In a recent episode, the series focuses on thyroid cancer. , ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... and Gynecology markets with innovative and proprietary products, will ... 31, 2017 after the market close on Tuesday, May ... a conference call and webcast to discuss its financial ... at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
(Date:4/18/2017)... DUBLIN , April 18, 2017 Research ... Devices Market 2017-2021" report to their offering. ... The global arthroscopy devices market to grow at ... The report, Global Arthroscopy Devices Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
Breaking Medicine Technology: